A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)

BACKGROUND: Very few data are available on treatment in HIV Late presenter population that still represents a clinical challenge. METHODS: Prospective, multicenter, randomized open-label, 2 arm, phase-3 trial comparing the 48-week virological response of two different regimens: abacavir/lamivudine +...

Descripción completa

Detalles Bibliográficos
Autores principales: Mussini, Cristina, Roncaglia, Enrica, Borghi, Vanni, Rusconi, Stefano, Nozza, Silvia, Cattelan, Anna Maria, Segala, Daniela, Bonfanti, Paolo, Di Biagio, Antonio, Barchi, Enrico, Focà, Emanuele, Degli Antoni, Anna, Bonora, Stefano, Francisci, Daniela, Limonta, Silvia, Antinori, Andrea, D’Ettorre, Gabriella, Maggiolo, Franco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764686/
https://www.ncbi.nlm.nih.gov/pubmed/31560700
http://dx.doi.org/10.1371/journal.pone.0222650

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764686/
https://www.ncbi.nlm.nih.gov/pubmed/31560700
http://dx.doi.org/10.1371/journal.pone.0222650

Ejemplares similares